Page last updated: 2024-09-05

sorafenib and Brain Neoplasms

sorafenib has been researched along with Brain Neoplasms in 61 studies

Research

Studies (61)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (14.75)	29.6817
2010's	48 (78.69)	24.3611
2020's	4 (6.56)	2.80

Authors

Authors	Studies
Meng, F; Ni, D; Qiu, X; Wei, J; Xia, Y; Zhong, Z	1
Cole, BL; Leary, SES; Lockwood, CM; Starr, K	1
Chen, QX; Cheng, J; Fan, YQ; Liu, BH; Wang, JM; Zhou, H	1
Beal, K; Grkovski, M; Holodny, A; Humm, JL; Jhaveri, KL; Morikawa, A; Patil, S; Schöder, H; Seidman, AD; Tang, K	1
Arneson, K; Attia, A; Chakravarthy, AB; Cmelak, AJ; Horn, L; Mondschein, J; Niermann, K; Puzanov, I; Stavas, M; Xia, F	1
Clavreul, A; Lautram, N; Menei, P; Montero-Menei, CN; Pourbaghi-Masouleh, M; Roger, E	1
Abrey, LE; Aldape, K; Chang, S; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Ebiana, VA; Gilbert, M; Kuhn, J; Levin, VA; Lieberman, F; Mehta, MP; Nghiemphu, PL; Prados, M; Robins, HI; Wen, P; Wright, JJ; Yung, WKA	1
Anderson, SK; Buckner, JC; Dancey, J; Erickson, BJ; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaluza, V; Sarkaria, JN; Schiff, D; Schwerkoske, JF; Stella, P; Twohy, E; Wright, J	1
Barbier, EL; Coquery, N; Lemasson, B; Rémy, C; Serduc, R	1
Clavreul, A; Lemaire, L; Menei, P; Pourbaghi-Masouleh, M; Roger, E; Tétaud, C	1
Baek, JH; Cho, JM; Hwang, SG; Jo, Y; Kim, EH; Kim, H; Kim, JS; Kim, JY; Sai, S; Yoon, M	1
Hu, D; Hu, Y; Li, J; Wang, X	1
Arai, S; Fukuda, K; Hirata, E; Matsui, J; Nishiyama, A; Ohtsubo, K; Onoda, N; Taira, S; Takeuchi, S; Taniguchi, H; Tanimoto, A; Wang, R; Yamada, T; Yamashita, K; Yano, S	1
Al-Harbi, H; Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; MacKenzie, M; North, S; Rini, BI; Vickers, MM	1
Anderson, SK; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Kimlinger, TK; Kumar, SK; Lafky, JM; Northfelt, DW; Uhm, JH	1
Amoroso, D; Andreuccetti, M; Falcone, A; Fontana, A; Galli, C; Galli, L; Landi, L; Lombardi, G; Porta, C; Zagonel, V; Zustovich, F	1
Dermeche, S; Gravis, G; Guerin, M; Salem, N; Walz, J	1
Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM	1
Agarwal, N; Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Lee, J; Mackenzie, M; North, S; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Tan, MH; Vaishampayan, UN; Wood, LA; Yuasa, T	1
Ackerl, M; Dieckmann, K; Flechl, B; Hainfellner, J; Hassler, MR; Marosi, C; Preusser, M; Sax, C; Widhalm, G; Wöhrer, A	1
Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC	1
Allen, JC; Bloom, MC; Cohen, KJ; Dhall, G; Eberhart, CG; Fisher, MJ; Goldberg, JD; Harter, DH; Hochman, T; Jones, DT; Karajannis, MA; Korshunov, A; Legault, G; Merkelson, A; Milla, SS; Pfister, SM; Resnick, AC; Sievert, AJ; Wisoff, JH; Zagzag, D	1
Black, EP; Karabakhtsian, RG; Massarweh, S; Moss, J; Napier, D; Romond, E; Slone, S; Wang, C; Weiss, H	1
Bambury, RM; Morris, PG	1
Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S	1
de Bont, ES; den Dunnen, WF; Hoving, EW; Kampen, KR; Lourens, HJ; Meeuwsen-de Boer, TG; Scherpen, FJ; Sie, M; Zomerman, WW	1
Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U	1
Albiges, L; Escudier, B	1
Brandon, VL; Chen, MY; Hsu, LC; Jandial, R; Jove, R; Li, G; Lin, J; Yang, F; Yin, Y; Zou, Z	1
Dai, Y; Liu, X; Sun, K; Wang, H	1
Dikomey, E; Köcher, S; Kriegs, M; Müller-Goebel, J; Petersen, C; Riedel, M; Rothkamm, K; Struve, N	1
Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L	1
Ferrière, JM; Grenier, N; Kilkoski, F; Ravaud, A; Sire, M; Wallerand, H	1
Hill, KL; Lipson, AC; Sheehan, JM	1
Asemissen, AM; Keilholz, U; Knoedler, M; Miller, K; Schmittel, A; Steiner, U; Thiel, E; Zimmermann, K	1
Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Szczylik, C; Zonierek, J	1
Johnston, KW; Walid, MS	1
Culine, S; Patard, JJ; Pouessel, D	1
Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ	1
Altieri, DC; Gilbert, CA; Raskett, CM; Ross, AH; Siegelin, MD	1
Demers, A; Green, MR; Li, L; Moser, RP; Ross, AH; Sheng, Z; Smith, TW; Zhu, LJ	1
Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V	1
Barbier, EL; Bouchet, A; Coquery, N; Le Duc, G; Lemasson, B; Maisin, C; Rémy, C; Robert, P; Serduc, R; Troprès, I	1
Clerc, J; Coriat, R; Goldwasser, F; Mir, O; Ropert, S	1
Allen, P; Jonasch, E; Mahajan, A; Tannir, N; Verma, J	1
Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X	1
Brown, RE; Buryanek, J; Pfister, S; Rytting, ME; Vats, TS; Wolff, JE	1
George, S; Hornick, JL; Jagannathan, JP; Ramaiya, NH; Shinagare, AB	1
Du, W; Gong, K; Wang, DL; Zhang, QJ; Zhou, JR	1
Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M	1
Chen, L; Lu, H; Luo, Q; Ruan, M; Shen, Y; Yu, Y; Zhu, R	1
Barbier, EL; Bouchet, A; Christen, T; Le Duc, G; Lemasson, B; Maisin, C; Rémy, C; Serduc, R	1
Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Gilbert, MR; Kuhn, J; Lamborn, KR; Lee, EQ; Levin, VA; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Wright, JJ; Yung, WK	1
Adenis, A; Alt, M; Caty, A; Fumagalli, I; Penel, N; Vanhuyse, M; Zini, L	1
Agarwal, S; Chi, M; Dudek, AZ; Elmquist, WF; Mittapalli, RK; Oberoi, R; Raza, A; Singhal, M	1
Barbieri, F; Carra, E; Daga, A; Favoni, RE; Florio, T; Marubbi, D; Pattarozzi, A	1
Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X	1
Jane, EP; Pollack, IF; Premkumar, DR	1
Culine, S; Pouessel, D	1
Imarisio, I; Paglino, C; Porta, C	1
Fenning, R; Gudena, V; Kizziah, M; Montero, AJ; Post, G; Verma, N	1

Trials

19 trial(s) available for sorafenib and Brain Neoplasms

Article	Year
A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging. Breast cancer research and treatment, 2021, Volume: 188, Issue:2 Topics: Brain; Brain Neoplasms; Breast Neoplasms; Female; Humans; Neuroimaging; Positron-Emission Tomography; Sorafenib	2021
A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases. Journal of neuro-oncology, 2017, Volume: 133, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Disease-Free Survival; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiosurgery; Sorafenib	2017
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. Journal of neuro-oncology, 2018, Volume: 136, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Sorafenib; Treatment Outcome	2018
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer, 2018, 04-01, Volume: 124, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Sirolimus; Sorafenib; Survival Rate	2018
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Sep-01, Volume: 19, Issue:17 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Proportional Hazards Models; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2013
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. Anticancer research, 2013, Volume: 33, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Survival Analysis; Temozolomide; Time Factors	2013
Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:8 Topics: Ascites; Astrocytoma; Brain Neoplasms; Child; Humans; Magnetic Resonance Imaging; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Sorafenib; Ventriculoperitoneal Shunt	2014
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. British journal of cancer, 2014, 05-27, Volume: 110, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Temozolomide; Treatment Outcome	2014
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro-oncology, 2014, Volume: 16, Issue:10 Topics: Adolescent; Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Child, Preschool; Female; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; MAP Kinase Signaling System; Mice; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome	2014
Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer. Future oncology (London, England), 2014, Volume: 10, Issue:15 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Receptors, Estrogen; Sorafenib; Tamoxifen; Treatment Outcome	2014
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. European urology, 2015, Volume: 68, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib	2015
Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:5 Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Incidence; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Rate	2010
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. Journal of neuro-oncology, 2011, Volume: 101, Issue:1 Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Brain Neoplasms; Cytochrome P-450 CYP3A; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib; Temozolomide	2011
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer, 2010, Aug-01, Volume: 116, Issue:15 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide	2010
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro-oncology, 2011, Volume: 13, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Distribution; Treatment Outcome; Young Adult	2011
Preliminary experience with personalized and targeted therapy for pediatric brain tumors. Pediatric blood & cancer, 2012, Jul-15, Volume: 59, Issue:1 Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Boronic Acids; Bortezomib; Brain Neoplasms; Child; Child, Preschool; Curcumin; Disease-Free Survival; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Infant; Male; Niacinamide; Phenylurea Compounds; Pyrazines; Pyridines; Sirolimus; Sorafenib; Survival Rate	2012
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. International journal of radiation oncology, biology, physics, 2013, Feb-01, Volume: 85, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Sorafenib; Temozolomide; Vascular Endothelial Growth Factor A	2013
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-oncology, 2012, Volume: 14, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; Young Adult	2012
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro-oncology, 2013, Volume: 15, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Survival Rate; Tissue Distribution	2013

Other Studies

42 other study(ies) available for sorafenib and Brain Neoplasms

Article	Year
Small, Smart, and LDLR-Specific Micelles Augment Sorafenib Therapy of Glioblastoma. Biomacromolecules, 2021, 11-08, Volume: 22, Issue:11 Topics: Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Micelles; Sorafenib	2021
The "SEED" Study: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric and Young Adult Patients with Recurrent or Refractory Brain Tumors. Frontiers in bioscience (Landmark edition), 2022, 07-12, Volume: 27, Issue:7 Topics: Brain Neoplasms; Child; Dasatinib; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Humans; Neoplasm Recurrence, Local; Patient Selection; Prospective Studies; Sorafenib; Young Adult	2022
ACSL4 suppresses glioma cells proliferation via activating ferroptosis. Oncology reports, 2020, Volume: 43, Issue:1 Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coenzyme A Ligases; Down-Regulation; Eicosapentaenoic Acid; Ferroptosis; Gene Expression Regulation, Neoplastic; Glioma; Humans; Hydroxyeicosatetraenoic Acids; Male; Middle Aged; RNA, Small Interfering; Sorafenib	2020
Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal? Journal of experimental & clinical cancer research : CR, 2017, 09-29, Volume: 36, Issue:1 Topics: Administration, Intranasal; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblastoma; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays	2017
Cluster versus ROI analysis to assess combined antiangiogenic therapy and radiotherapy in the F98 rat-glioma model. NMR in biomedicine, 2018, Volume: 31, Issue:8 Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Cluster Analysis; Disease Models, Animal; Glioma; Magnetic Resonance Imaging; Male; Rats, Inbred F344; Sorafenib	2018
Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma. Drug delivery, 2018, Volume: 25, Issue:1 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Compounding; Drug Delivery Systems; Glioblastoma; Humans; Lipids; Mice; Mice, Nude; Nanocapsules; Sorafenib	2018
Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy. International journal of molecular sciences, 2018, Nov-21, Volume: 19, Issue:11 Topics: Animals; Antineoplastic Agents; Autophagy; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Combined Modality Therapy; Electric Stimulation Therapy; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Sorafenib	2018
Symptomatic treatment of brain metastases in renal cell carcinoma with sorafenib. Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:Supplement Topics: Aged; Asian People; Brain Neoplasms; Carcinoma, Renal Cell; Fatal Outcome; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Lung Neoplasms; Protein Kinase Inhibitors; Retreatment; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome	2018
Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. Molecular cancer therapeutics, 2019, Volume: 18, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Heterografts; Humans; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Carcinoma, Anaplastic	2019
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clinical genitourinary cancer, 2013, Volume: 11, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Databases, Factual; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival; Treatment Outcome	2013
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up. World journal of surgical oncology, 2013, Sep-27, Volume: 11 Topics: Adult; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lung Neoplasms; Mediastinal Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome	2013
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Eligibility Determination; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome	2014
Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study. Anti-cancer drugs, 2014, Volume: 25, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult	2014
Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma. Anti-cancer drugs, 2014, Volume: 25, Issue:6 Topics: Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib	2014
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. Journal of cellular physiology, 2015, Volume: 230, Issue:1 Topics: Anoikis; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; bcl-X Protein; Beclin-1; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Drug Synergism; ErbB Receptors; fas Receptor; Fas-Associated Death Domain Protein; Glioblastoma; Humans; Lapatinib; Lysosomal-Associated Membrane Protein 2; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Quinazolines; Sorafenib; TOR Serine-Threonine Kinases; Unfolded Protein Response	2015
Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma. PloS one, 2015, Volume: 10, Issue:3 Topics: Apoptosis; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Crizotinib; Dasatinib; Ependymoma; Extracellular Signal-Regulated MAP Kinases; Humans; Intercellular Signaling Peptides and Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Signal Transduction; Sorafenib	2015
Sorafenib-Sunitinib Sequence: The Jury Is Out. European urology, 2015, Volume: 68, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib	2015
Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3. Journal of neurosurgery, 2016, Volume: 124, Issue:5 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Convection; Heterografts; Humans; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; STAT3 Transcription Factor; Transcriptional Activation	2016
Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma. Cellular and molecular neurobiology, 2016, Volume: 36, Issue:7 Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Glioblastoma; Male; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib	2016
Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines. Oncotarget, 2016, Sep-20, Volume: 7, Issue:38 Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Glioblastoma; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Radiation Tolerance; Signal Transduction; Sorafenib; X-Rays	2016
Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. Journal of neuro-oncology, 2009, Volume: 91, Issue:1 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Cortex; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2009
[Anti-angiogenic treatment in the management of metastatic renal cell carcinoma]. Bulletin du cancer, 2008, Volume: 95, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib	2008
Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. Journal of neurosurgery, 2009, Volume: 111, Issue:3 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain; Brain Edema; Brain Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Seizures; Sorafenib; Sunitinib	2009
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology, 2009, Volume: 76, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Salvage Therapy; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome	2009
Successful treatment of a brain-metastasized renal cell carcinoma. German medical science : GMS e-journal, 2009, Oct-21, Volume: 7 Topics: Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Parietal Lobe; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Receptors, Vascular Endothelial Growth Factor; Sorafenib	2009
[Advanced renal carcinomas with special situations. How to treat them?]. Bulletin du cancer, 2010, Volume: 97 Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2010
Sorafenib exerts anti-glioma activity in vitro and in vivo. Neuroscience letters, 2010, Jul-12, Volume: 478, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glioblastoma; Glioma; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Random Allocation; Sorafenib; Treatment Outcome	2010
A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nature medicine, 2010, Volume: 16, Issue:6 Topics: Activating Transcription Factors; Animals; Apoptosis; Benzenesulfonates; Brain Neoplasms; Cyclic AMP Response Element-Binding Protein; Gene Expression Profiling; Glioma; Humans; Mice; Mice, Inbred C57BL; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Sorafenib; Tumor Cells, Cultured	2010
Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media. Radiology, 2010, Volume: 257, Issue:2 Topics: Analysis of Variance; Animals; Area Under Curve; Benzenesulfonates; Blood-Brain Barrier; Brain Neoplasms; Contrast Media; Disease Models, Animal; Glioma; Heterocyclic Compounds; Macromolecular Substances; Magnetic Resonance Imaging; Male; Neovascularization, Pathologic; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Pyridines; Random Allocation; Rats; Sorafenib	2010
A painful cranial bulge. Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779 Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Middle Aged; Niacinamide; Occipital Bone; Pain; Parietal Bone; Phenylurea Compounds; Pyridines; Skull Neoplasms; Sorafenib; Temporal Bone; Thyroglobulin; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome	2011
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer, 2011, Nov-01, Volume: 117, Issue:21 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib	2011
Intracranial metastasis from pediatric GI stromal tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Apr-01, Volume: 30, Issue:10 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Stomach Neoplasms; Sunitinib; Treatment Outcome	2012
Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. World journal of surgical oncology, 2012, Apr-21, Volume: 10 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Glioma; Humans; Immunoenzyme Techniques; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; raf Kinases; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Vitamin K 1; Vitamins	2012
Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib. Thyroid : official journal of the American Thyroid Association, 2012, Volume: 22, Issue:8 Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome	2012
Evaluation of the relationship between MR estimates of blood oxygen saturation and hypoxia: effect of an antiangiogenic treatment on a gliosarcoma model. Radiology, 2012, Volume: 265, Issue:3 Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Benzenesulfonates; Brain Neoplasms; Dextrans; Gliosarcoma; Hypoxia, Brain; Image Processing, Computer-Assisted; Immunohistochemistry; Linear Models; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Niacinamide; Nitroimidazoles; Oxygen; Phenylurea Compounds; Pyridines; Random Allocation; Rats; Rats, Inbred F344; Reproducibility of Results; Sorafenib	2012
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma? Bulletin du cancer, 2012, Volume: 99, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Cancer Care Facilities; Carcinoma, Renal Cell; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome	2012
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clinical genitourinary cancer, 2013, Volume: 11, Issue:2 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Knockout; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome	2013
Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell cycle (Georgetown, Tex.), 2013, Feb-01, Volume: 12, Issue:3 Topics: Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Differentiation; Cell Proliferation; Down-Regulation; Glioblastoma; Humans; Intermediate Filament Proteins; Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Nerve Tissue Proteins; Nestin; Niacinamide; Oligodendrocyte Transcription Factor 2; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sorafenib; SOXB1 Transcription Factors; STAT3 Transcription Factor; Tumor Cells, Cultured	2013
Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:3 Topics: Acetophenones; Annexin A5; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzopyrans; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Proliferation; Cell Survival; Clone Cells; Drug Synergism; Enzyme Inhibitors; Glioma; Humans; Immunohistochemistry; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Folding; Protein Kinase C; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A	2006
High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. European urology, 2008, Volume: 53, Issue:2 Topics: Adult; Aged; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib	2008
Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008; European urology, 2008, Volume: 53, Issue:5 Topics: Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; France; Humans; Incidence; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Treatment Outcome	2008
Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. Cancer biology & therapy, 2008, Volume: 7, Issue:6 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Nerve Sheath Neoplasms; Neurilemmoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiography, Thoracic; Sorafenib; Thoracic Wall; Treatment Outcome	2008